Our Experience
Our extensive experience enables us to craft innovative solutions to address our clients’ strategic and financial goals.
In depth expertise across life science transactions.
Select Transactions
M&A
Acquisition by Eli Lilly
Acquisition by Eli Lilly
OVERVIEW: Sale of clinical-stage company, including its lead product candidate, Ixo-vec, a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose.
AMOUNT: $262,000,000+
CLOSE DATE: December 2025
Acquisition by Takara Bio USA
Acquisition by Takara Bio USA
OVERVIEW: Sale of single-cell spatial biology tools company.
AMOUNT: 190,500,000
CLOSE DATE: January 2025
Acquisition by Eli Lilly
Acquisition by Eli Lilly
OVERVIEW: Sale of preclinical therapeutics company developing a platform technology with initial applications in metabolic disease.
AMOUNT: $1,000,000,000+
CLOSE DATE: June 2021
Partnering
Licensing Agreement with Novartis
Licensing Agreement with Novartis
OVERVIEW: Exclusive option and license agreement for oral covalent inhibitors directed at a transcription factor linked to a number of inflammatory diseases.
AMOUNT: $1,000,000,000+
CLOSE DATE: July 2025
Licensing Agreement with AbbVie
Licensing Agreement with AbbVie
OVERVIEW: Option agreement for license to develop and commercialize reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis.
AMOUNT: $400,000,000+
CLOSE DATE: November 2023
Partnership with Sanofi
Partnership with Sanofi
OVERVIEW: Collaboration to develop and commercialization IRAK4 protein degrader therapies for immune-inflammatory diseases.
AMOUNT: $2,150,000,000+
CLOSE DATE: August 2020
Financing
Series B Preferred Stock
Series B Preferred Stock
OVERVIEW: Financing for oncology diagnostics leveraging AI for new, morphology-driven disease analysis.
AMOUNT: $20,700,000
CLOSE DATE: August 2024
Series D Preferred Stock
Series D Preferred Stock
OVERVIEW: Series C financing round for commercial-stage best-in-class epilepsy company.
AMOUNT: $114,000,000
CLOSE DATE: March 2021
Series A Preferred Stock
Series A Preferred Stock
OVERVIEW: Series A financing round, alongside a concurrent asset acquisition and operational company formation.
AMOUNT: $275,000,000
CLOSE DATE: October 2019
Transaction History
Strategic Investment by Hanmi
Strategic Investment by Hanmi
OVERVIEW: Strategic investment and out-licensing of lead product in Korea and China
AMOUNT: $20,000,000+
CLOSE DATE: January 2015
Acquisition of SPRIX from Luitpold
Acquisition of SPRIX from Luitpold
OVERVIEW: Acquisition of SPRIX, a marketed pain management therapeutic, from Luitpold Pharmaceuticals
AMOUNT: N/A
CLOSE DATE: January 2015
Partnership with Curetech
Partnership with Curetech
OVERVIEW: In-licensing of clinical stage anti-PD-1 immunotherapy, Pidilizumab
AMOUNT: $335,000,000
CLOSE DATE: October 2014
Acquisition by Nicox S.A.
Acquisition by Nicox S.A.
OVERVIEW: Sale of a privately held, venture-backed ophthalmology therapeutics company
AMOUNT: $120,000,000
CLOSE DATE: July 2014
Series B Preferred Stock & Debt
Series B Preferred Stock & Debt
OVERVIEW: Growth capital for private, commercial-stage hip and knee implant company
AMOUNT: $43,400,000
CLOSE DATE: April 2014
Acquisition of SPL
Acquisition of SPL
OVERVIEW: Acquisition of privately held manufacturer and supplier of heparin
AMOUNT: $337,500,000+
CLOSE DATE: January 2014
Acquisition by Becton Dickinson
Acquisition by Becton Dickinson
OVERVIEW: Sale of a privately held diagnostic instrument company with a commercialize product in the point-of-care market
AMOUNT: $40,000,000
CLOSE DATE: January 2014
Africa, Middle East & CIS Partnership with Sanofi
Africa, Middle East & CIS Partnership with Sanofi
OVERVIEW: License and commercialization agreement with Sanofi for avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia
AMOUNT: $61,000,000
CLOSE DATE: December 2013
Series C Preferred Stock
Series C Preferred Stock
OVERVIEW: Series C financing for AXIOS family of devices and interventional endoscopy platform
AMOUNT: $25,000,000
CLOSE DATE: December 2013
North American Partnership with Auxilium
North American Partnership with Auxilium
OVERVIEW: License agreement providing Auxilium the exclusive rights to STENDRA™ (avanafil) in the US and Canada
AMOUNT: $300,000,000
CLOSE DATE: October 2013
Acquisition by Actelion
Acquisition by Actelion
OVERVIEW: Sale of Ceptaris Therapeutics, a privately held US-based specialty pharmaceutical company, to Actelion
AMOUNT: $250,000,000+
CLOSE DATE: September 2013
European Partnership with Menarini
European Partnership with Menarini
OVERVIEW: Licensing agreement with Menarini to commercialize and promote SPEDRA™ (avanafil) in over 40 European countries plus Australia and New Zealand
AMOUNT: $100,000,000
CLOSE DATE: July 2013
Acquisition by Pfizer
Acquisition by Pfizer
OVERVIEW: Sale of a biotechnology company developing a treatment for ADHD and other related CNS disorders.
AMOUNT: $700,000,000
CLOSE DATE: October 2012
European Partnership with Baxter
European Partnership with Baxter
OVERVIEW: European licensing agreement with Baxter for a Phase 3, anti-cancer compound Rigosertib
AMOUNT: $812,500,000
CLOSE DATE: September 2012
Strategic Investment by Baxter
Strategic Investment by Baxter
OVERVIEW: Strategic investment by Baxter into Onconova Therapeutics, a biotechnology company developing a Phase 3, anti-cancer compound Rigosertib
AMOUNT: $50,000,000
CLOSE DATE: 2012
Acquisition by Bionomics
Acquisition by Bionomics
OVERVIEW: Sale of a privately held biotechnology company focused on developing novel therapeutic product candidates that target cancer stem cells in oncology
AMOUNT: N/A
CLOSE DATE: September 2012
Acquisition by Sanofi
Acquisition by Sanofi
OVERVIEW: Sale of a specialty pharmaceutical company focusing on the development and commercialization of pediatric and dermatology pharmaceutical products
AMOUNT: $207,500,000
CLOSE DATE: October 2011
Series B Preferred Stock
Series B Preferred Stock
OVERVIEW: Series B financing for healthcare equipment company focused on vein visualization solutions
AMOUNT: $22,500,000
CLOSE DATE: July 2011
Series C Preferred Stock
Series C Preferred Stock
OVERVIEW: Series C financing to commercialize NEXICLON™XR for the treatment of hypertension and prepare for novel extended-release liquid methylphenidate for ADHD
AMOUNT: $45,000,000
CLOSE DATE: January 2011
Acquisition of ROXRO PHARMA
Acquisition of ROXRO PHARMA
OVERVIEW: Acquisition of a specialty pharmaceutical company with an FDA-approved drug for pain.
AMOUNT: N/A
CLOSE DATE: December 2010
Acquisition by OriGene
Acquisition by OriGene
OVERVIEW: Sale of a gene synthesis company while spinning out a new oligonucleotide synthesis technology into a new company.
AMOUNT: N/A
CLOSE DATE: August 2010
Acquisition of PharmaForce, Inc.
Acquisition of PharmaForce, Inc.
OVERVIEW: Sale of a fully integrated specialty injectable generic pharmaceutical company
AMOUNT: N/A
CLOSE DATE: December 2009
Acquisition by Clarient
Acquisition by Clarient
OVERVIEW: Sale of a tools company for the detection and classification of human cancer.
AMOUNT: N/A
CLOSE DATE: December 2009
Partnership with Astellas
Partnership with Astellas
OVERVIEW: Global licensing and commercialization agreement with Astellas for MDV3100, anti-androgen drug candidate for prostate cancer.
AMOUNT: $765,000,000+
CLOSE DATE: October 2009
Series B Preferred Stock
Series B Preferred Stock
OVERVIEW: Financing of specialty pharmaceutical company focused on women’s healthcare and pain management.
AMOUNT: $50,000,000
CLOSE DATE: October 2009
Acquisition by Roche
Acquisition by Roche
OVERVIEW: Sale of a developer of a functional antibody discovery platform.
AMOUNT: $184,000,000
CLOSE DATE: September 2008
Acquisition by Tethys Bioscience
Acquisition by Tethys Bioscience
OVERVIEW: Sale of a clinical diagnostic tools company.
AMOUNT: N/A
CLOSE DATE: September 2008
Acquisition by Thermo Fisher
Acquisition by Thermo Fisher
OVERVIEW: Sale of a provider of RNAi, gene expression, and protein detection products.
AMOUNT: N/A
CLOSE DATE: June 2008
Acquisition by Ocimum
Acquisition by Ocimum
OVERVIEW: Sale of drug discovery company’s Genomics Division.
AMOUNT: $10,000,000
CLOSE DATE: December 2007
Series C Preferred Stock
Series C Preferred Stock
OVERVIEW: Financing for clinical stage immuno-therapeutics company.
AMOUNT: $41,200,000
CLOSE DATE: September 2007
Acquisition by LabCorp
Acquisition by LabCorp
OVERVIEW: Sale of company focused on robotic systems and automation solutions for diagnostic testing and biomedical research processes.
AMOUNT: N/A
CLOSE DATE: May 2007
Series E Preferred Stock
Series E Preferred Stock
OVERVIEW: Series E financing for late-stage biopharma company.
AMOUNT: $44,000,000
CLOSE DATE: May 2007
Series C Preferred Stock
Series C Preferred Stock
OVERVIEW: Series C financing for company with approved point-of-care blood diagnostic platform.
AMOUNT: $31,000,000
CLOSE DATE: April 2007
Series C Preferred Stock
Series C Preferred Stock
OVERVIEW: Series C financing for commercial-stage biologics company focused on respiratory and inflammatory diseases.
AMOUNT: $60,000,000
CLOSE DATE: May 2006
Series B Preferred Stock & Debt
Series B Preferred Stock & Debt
OVERVIEW: Series B financing for commercial-stage specialty biopharmaceutical company.
AMOUNT: $85,000,000
CLOSE DATE: November 2006
Acquisition by Genetix
Acquisition by Genetix
OVERVIEW: Sale of company focused on automated imaging and image analysis systems.
AMOUNT: $25,200,000
CLOSE DATE: November 2006
Acquisition by Nektar
Acquisition by Nektar
OVERVIEW: Sale of respiratory device company.
AMOUNT: $32,000,000
CLOSE DATE: October 2005
Acquisition by Invitrogen
Acquisition by Invitrogen
OVERVIEW: Sale of biomolecular detection company.
AMOUNT: N/A
CLOSE DATE: October 2005
Acquisition by Fisher Scientific
Acquisition by Fisher Scientific
OVERVIEW: Sale of systems provider for High Content Screening and High Content Analysis.
AMOUNT: $49,000,000
CLOSE DATE: September 2005
Acquisition by Agilent Technologies
Acquisition by Agilent Technologies
OVERVIEW: Sale of software company for gene expression analysis.
AMOUNT: N/A
CLOSE DATE: October 2004
Series C Preferred Stock
Series C Preferred Stock
OVERVIEW: Series C financing for pain management company.
AMOUNT: $65,000,000
CLOSE DATE: February 2004